Michael Monheit is the managing partner of Monheit Law, a Pennsylvania-based law firm. Monheit Law has partnered with several law firms that sponsor the Zofran Legal Center, a resource center for those who took Zofran during pregnancy and delivered a child with a congenital birth defect.
On October 13, 2016, GlaxoSmithKline asked a federal court to dismiss all Zofran lawsuits that involve the anti-nausea drug’s generic equivalents. In a second motion, filed the same day, the company requested that all claims based in allegations of fraud be struck from the lawsuits. Plaintiffs…
Two more Zofran lawsuits have been transferred to the US District Court of Massachusetts. In their complaints, women from Mississippi and Texas claim the potent anti-nausea drug holds the potential to cause major birth defects. With these most recent filings, a total of 282 lawsuits…
In a new Zofran lawsuit, filed on October 3, 2016, a mother from Oneida, New York claims the drug’s active ingredient caused her son to develop cleft palate and cleft lip in the womb. The woman’s case, logged as number 1:16-cv-11980-FDS, was filed directly in the…
Zofran is a potent anti-nausea medication manufactured by GlaxoSmithKline. And while Zofran’s active ingredient, ondansetron, has never been approved for use during pregnancy, doctors frequently prescribe the drug “off-label” as a treatment for morning sickness. But hundreds of families say that Zofran causes major birth defects.…
In a new Zofran lawsuit, parents from Brazoria, Texas – a city just outside Houston – say that GlaxoSmithKline’s potent anti-nausea drug led to tragic results in two pregnancies. Their first child, exposed to Zofran during the first trimester of pregnancy, died within a month…
To date, more than 280 families have filed Zofran birth defect lawsuits in the US District Court for Massachusetts – where the litigation has been “consolidated” for pre-trial proceedings. In Boston, these cases will proceed through several critical stages of the litigation process together. The…
